

Chara Papadaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4593553/publications.pdf>

Version: 2024-02-01

40
papers

972
citations

516561

16
h-index

454834

30
g-index

41
all docs

41
docs citations

41
times ranked

1518
citing authors

#	ARTICLE	IF	CITATIONS
1	TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications. <i>Cancers</i> , 2022, 14, 1053.	1.7	7
2	MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. <i>Biomedicines</i> , 2021, 9, 421.	1.4	2
3	Mir-34a as predictor of immunotherapy efficacy in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21191-e21191.	0.8	1
4	Investigation of TLR4 and pSTAT3 expression on tumor and immune cells in the peripheral blood (PB) of patients with breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e15015-e15015.	0.8	0
5	MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 668534.	1.6	14
6	Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. <i>PLoS ONE</i> , 2021, 16, e0252537.	1.1	20
7	A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 1988.	1.8	9
8	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3538-3549.	1.3	21
9	Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 8257-8271.	0.9	3
10	PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2058.	1.7	14
11	Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 901-913.	0.5	1
12	Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. <i>Cancers</i> , 2020, 12, 376.	1.7	52
13	Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study. <i>Cancers</i> , 2020, 12, 1013.	1.7	17
14	MicroRNAs involved in immune response as prognostic markers in early and metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15528-e15528.	0.8	2
15	Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. <i>Cancers</i> , 2020, 12, 1282.	1.7	17
16	Cancer cachexia syndrome in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a single-institution, prospective, observational study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21644-e21644.	0.8	0
17	Intergration of common clinical and laboratory parameters for predictive modeling of outcome with immune checkpoint inhibitors (ICIs) in patients (pts) with Non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21609-e21609.	0.8	2
18	Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): A prospective, observational study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9099-9099.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. <i>Oncotarget</i> , 2019, 10, 966-981.	0.8	38
20	Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1518-1526.	1.3	10
21	Role of the expression of PD-L1 and CD47 on circulating tumor cells (CTCs) in the prediction of outcome in metastatic breast cancer (mBC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14045-e14045.	0.8	3
22	Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 72.	2.2	69
23	Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 767-775.	1.1	19
24	Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy. <i>Pharmacogenomics Journal</i> , 2017, 17, 506-514.	0.9	16
25	ERCC1SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. <i>Cancer Investigation</i> , 2015, 33, 107-113.	0.6	13
26	PKM2 and CD44 tumoral expression to predict the effectiveness of front-line paclitaxel and carboplatin chemotherapy in epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16564-e16564.	0.8	0
27	PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2014, 111, 1757-1764.	2.9	53
28	Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP1IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. <i>PLoS ONE</i> , 2013, 8, e74611.	1.1	31
29	BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients' Outcome. <i>PLoS ONE</i> , 2013, 8, e84604.	1.1	48
30	Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPO-I, TOPO-iiA, TOPO-iiB, and c-MYC genes in patients with small cell lung cancer (SCLC) who received first-line therapy with cisplatin and etoposide.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7594-7594.	0.8	0
31	ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 663-671.	0.5	58
32	Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in 2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients. <i>PLoS ONE</i> , 2011, 6, e15980.	1.1	114
33	Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2011, 104, 316-323.	2.9	31
34	Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 165-173.	3.2	19
35	Tumoral Expression of TXR1 and TSP1 Predicts Overall Survival of Patients with Lung Adenocarcinoma Treated with First-line Docetaxel-Gemcitabine Regimen. <i>Clinical Cancer Research</i> , 2009, 15, 3827-3833.	3.2	35
36	Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2008, 3, e3695.	1.1	121

#	ARTICLE	IF	CITATIONS
37	The RAS-dependent ERF Control of Cell Proliferation and Differentiation Is Mediated by c-Myc Repression. <i>Journal of Biological Chemistry</i> , 2007, 282, 30285-30294.	1.6	24
38	Transcriptional Repressor Erf Determines Extraembryonic Ectoderm Differentiation. <i>Molecular and Cellular Biology</i> , 2007, 27, 5201-5213.	1.1	34
39	The upstream regulatory region of the gene for the human homologue of the adhesion molecule TAG-1 contains elements driving neural specific expression in vivo. <i>Molecular Brain Research</i> , 2003, 118, 91-101.	2.5	10
40	Regional distribution and cell type-specific expression of the mouse F3 axonal glycoprotein: A developmental study. , 1999, 413, 357-372.		42